CCND2 and miR-206 as potential biomarkers in the clinical diagnosis of thyroid carcinoma by fine-needle aspiration cytology

Abstract

Background To investigate the relationship between cyclin D2 (CCND2) and miR-206 expression in fine-needle aspiration cytology of thyroid carcinoma. Methods A total of 65 patients with thyroid carcinoma were selected as the subjects and 65 patients with benign thyroid nodules were in control group. The fine-needle aspiration cytology of thyroid nodules was performed. CCND2 and miR-206 levels were detected by PCR. Results Compared with the patients with benign thyroid nodules, the expression level of miR-206 in fine-needle aspiration cytology of thyroid cancer patients decreased significantly and the expression level of CCND2 increased significantly. CCND2 and miR-206 expression was negatively correlated in thyroid cancer tissues. Area under curve (AUC) of miR-206 level in the diagnosis of thyroid cancer was 0.889, and the sensitivity and specificity were 92.3% and 81.5%, respectively. AUC of CCND2 level in the diagnosis of thyroid cancer was 0.837, and the sensitivity and specificity were 67.7% and 89.2%, respectively. The AUC of combined detection of CCND2 and miR-206 in the diagnosis of thyroid cancer was 0.959, and the sensitivity and specificity were 93.8% and 87.7%, respectively. The levels of miR-206 and CCND2 were significantly correlated with TNM staging and lymph node metastasis. Conclusions miR-206 and CCND2 may become new biomarkers for clinical diagnosis of thyroid cancer based on the fine-needle aspiration cytology of thyroid nodules.

The diagnostic performance of microRNAs expression levels in cellular aspirate of solitary thyroid nodule overrides that of cytology

“…21,22 Recently, Yuan et al detected significantly decreased expression level of miR-206 in TC FNAC with high sensitivity and specificity and found negative relation between miR-206 expression levels and TNM staging and lymph node metastasis. 23 Regarding miR-203a, detected down-regulated expression levels of miR-203a supported that previously reported by Wu et al who detected significantly lower expression levels of miR-203 in PTC tissues in comparison to normal controls and concluded that miR-203 could function as biomarker for PTC. 24 Also, Zhu et al detected decreased levels of miR-203 in relation to adjacent normal tissues and normal thyroid tissues and found miR-203 was implicated in tumor stage and lymphnode metastasis and can detect PTC with high sensitivity and specificity rates of 73.7%, and 84%, respectively and concluded that miR-203 satisfactory diagnostic value in PTC and its upregulation can inhibit PTC cell growth and promote cell apoptosis.…”

Analysis of Under-Diagnosed Malignancy during Fine Needle Aspiration Cytology of Lymphadenopathies

“…A recent report described an interesting idea involving the use of cytologic samples not only for diagnostic purposes but also for ancillary testing [22]. Yuan et al applied this concept during the FNAC analysis of thyroid nodules, measuring the levels of CCND2 and miR-206, identified as thyroid carcinoma biomarkers, directly by PCR after performing FNAC [23]. The process significantly reduced the number of procedures required to obtain an adequate biopsy sample while improving the accuracy of FNAC diagnosis.…”

Exploring the Feasibility of Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Osteoarthritis: Challenges and Opportunities

“…This effect was mediated by inhibition of the glucose-6-phosphate dehydrogenase (G6PD) gene, highlighting the precise regulatory role of miR-206 in cellular growth and development [46]. In addition to skeletal muscle development, miR-206 acts as a tumor suppressor by regulating the expression of different genes, such as Sox9 [47], Cyclin D2 [48], Notch 3 [49], and FMNL2 [50], in various tissues. miRNA-206 is also downregulated and suppresses cell proliferation by targeting Forkhead box protein 1 (FOXP1) in brain gliomas [51].…”